Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1467511 | 0.98 | — | — | |
| Acetic Acid SCHEMBL3134326 | 0.86 | ALDH1A1 (0.60) | — | |
| Hydrochloric Acid SCHEMBL5013504 | 0.77 | ALDH1A1 (0.59) | — | |
| SCHEMBL14434069 | 0.74 | — | — | |
| SCHEMBL158422 | 0.74 | — | — | |
| SCHEMBL1314765 | 0.74 | — | — | |
| Potassium SCHEMBL31461086 | 0.73 | — | — | |
| SCHEMBL31461084 | 0.73 | — | — | |
| SCHEMBL31461088 | 0.73 | — | — | |
| SCHEMBL10173369 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110204539-B | Dihydropyrimidine prodrug and preparation method and application thereof | 山东大学 | 2021-07-23 | — | — | CN | claimed |
| CN-109232555-B | anti-HBV oxygen-containing heterocyclic compound | 深圳市第二人民医院 | 2020-06-02 | — | — | CN | claimed |
| CN-109251201-B | anti-HBV nitrogen-containing heterocyclic compound | 深圳市第二人民医院 | 2020-06-02 | — | — | CN | claimed |
| EP-4698521-A1 | PROCESS FOR THE PREPARATION OF 4-HYDROXY-4,5-DIHYDROTHIAZOLE-2-CARBONITRILE AND DERIVATIVES THEREOF | F. Hoffmann-La Roche AG (CH) | 2026-02-25 | — | — | EP | disclosed |
| US-20250304597-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-10-02 | — | — | US | disclosed |
| US-12351575-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2025-07-08 | — | — | US | disclosed |
| CN-120157666-A | Dihydropyrimidine compound, preparation method and application thereof, dihydropyrimidine derivative and application thereof, pharmaceutical composition and application thereof | 中国医学科学院医药生物技术研究所 | 2025-06-17 | — | — | CN | disclosed |
| CN-119176804-A | Amidopyrroles and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| EP-3695837-B1 | A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR FOR TREATING HEPATITIS B | HOFFMANN LA ROCHE (CH) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024218026-A1 | PROCESS FOR THE PREPARATION OF 4-HYDROXY-4,5-DIHYDROTHIAZOLE-2-CARBONITRILE AND DERIVATIVES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2024-10-24 | — | — | WO | disclosed |
| US-20240246978-A1 | PHENYLDIHYDROPYRIMIDINE COMPOUND AND USE THEREOF | Hepagene Therapeutics (HK) Limited (CN) | 2024-07-25 | — | — | US | disclosed |
| US-20060293326-A1 | 2-Heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases | BAYER HEALTHCARE AG (DE) | 2006-12-28 | — | — | US | disclosed |
| EP-1399439-B1 | 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES | BAYER HEALTHCARE AG (DE) | 2006-06-14 | — | — | EP | disclosed |
| EP-1399439-A1 | 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES | Bayer HealthCare AG (DE) | 2004-03-24 | — | — | EP | disclosed |
| US-6503913-B1 | Treatment of hepatitis B virus infections | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-07 | — | — | US | disclosed |
| WO-2002098873-A1 | 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
| EP-1073653-B1 | NOVEL 2-HETEROCYCLICALLY SUBSTITUTED DIHYDROPYRIMIDINES | BAYER AG (DE) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001068647-A1 | MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| EP-1073653-A1 | NOVEL 2-HETEROCYCLICALLY SUBSTITUTED DIHYDROPYRIMIDINES | BAYER AG (DE) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999054329-A1 | NOVEL 2-HETEROCYCLICALLY SUBSTITUTED DIHYDROPYRIMIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-10-28 | — | — | WO | disclosed |